HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up

Sino Biopharmaceutical

11/05/2026 07:28

** Shares of Sino Biopharmaceutical 1177.HK climb 4.2% to HK$5.66, their highest point since April 27

** Stock set for the biggest one-day pct gain since April 15; top pct gainer in Hang Seng Biotech Index .HSBIO, which adds 0.8%

** The Chinese pharmaceutical group said its unit Chia Tai Tianqing Pharmaceutical Group entered into an exclusive strategic collaboration with GlaxoSmithKline (GSK) to accelerate bepirovirsen, which is for treatment of chronic hepatitis B, in mainland China at launch

** Says its unit will purchase bepirovirsen from GSK under agreed supply terms for an initial term of 5.5 years and will be responsible for importation, distribution, and hospital access of bepirovirsen in mainland China, while GSK will remain the marketing authorization holder

** YTD, stock down 8.7%, while benchmark Hang Seng Index .HSI up 3.1%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))